Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 1.00 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.90 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.90 |
| ▸ | RXRB | P28702 | 11/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | RXRG | P48443 | 6/20 | 0.58 |
| ▸ | RARB | P10826 | 5/20 | 0.58 |
| ▸ | RARG | P13631 | 5/20 | 0.58 |
| ▸ | RARA | P10276 | 3/20 | 0.56 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808583 | 0.95 | RXRA (1.00) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL8706133 | 0.86 | RXRA (0.76) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL8707221 | 0.85 | RXRA (0.74) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL3454051 | 0.85 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL29391180 | 0.85 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL31061276 | 0.85 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL8706853 | 0.83 | RXRA (0.71) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL7752831 | 0.81 | RXRA (0.68) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL8708782 | 0.81 | RXRA (0.74) | RXRACYP26B1CYP26A1RXRBCYP3A4 | |
| SCHEMBL3453249 | 0.79 | RXRA (1.00) | RXRACYP26B1CYP26A1RXRBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087231-B2 | Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system | INTREXON CORPORATION (US) | 2018-10-02 | — | — | US | claimed |
| US-20170015728-A1 | Novel Substitution Mutant Receptors and Their Use in an Ecdysone Receptor-Based Inducible Gene Expression System | INTREXON CORPORATION (US) | 2017-01-19 | — | — | US | claimed |
| EP-1534738-B1 | NOVEL SUBSTITUTION MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2012-06-20 | — | — | EP | claimed |
| US-7045315-B2 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2006-05-16 | — | — | US | claimed |
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE OF BIOLOGICAL STUDIES | 2002-12-12 | — | — | US | claimed |
| EP-1076569-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-02-21 | — | — | EP | claimed |
| WO-1999058155-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-11-18 | — | — | WO | claimed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE OF BIOLOGICAL STUDIES | 2002-12-12 | — | — | US | disclosed |
| WO-2002094877-A2 | NEW NUCLEAR RECEPTOR COFACTORS AND RELATED MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002086064-A2 | INDUCIBLE EXPRESSION OF TRANSFECTED GENES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | disclosed |
| EP-1076569-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999058155-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | NR2E3, GFRA2, GFRA3 | RXRA 691/4885CYP26B1 966/4885CYP26A1 694/4885 |
| US-20170015728-A1 | Novel Substitution Mutant Receptors and Their Use in an Ecdysone Receptor-Based Inducible Gene Expression System | NR2E3, ESRRB, GHITM | RXRA 47/4885CYP26B1 120/4885CYP26A1 116/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | RXRA 4071/4885CYP26B1 1271/4885CYP26A1 763/4885 |
| US-10087231-B2 | Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system | NR2E3, ESRRB, GHITM | RXRA 54/4885CYP26B1 118/4885CYP26A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.